Aardvark Therapeutics (AARD) Profit After Tax (2024 - 2026)

Aardvark Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$21.6 million in Q1 2026.

• Quarterly Profit After Tax fell 131.88% year-over-year to -$21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.9 million (down 152.05% YoY) and the FY2025 annual result came in at -$57.6 million, down 179.73% from the prior year.
• Profit After Tax fell to -$21.6 million in Q1 2026 per AARD's latest filing, from -$17.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$2.2 million in Q1 2024 and troughed at -$21.6 million in Q1 2026.
• A 3-year average of -$11.1 million and a median of -$9.3 million in 2025 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 100.46% in 2025, down 327.46% in 2025.
• Over 3 years, Profit After Tax stood at -$8.8 million in 2024, then plunged by 100.46% to -$17.6 million in 2025, then fell by 22.67% to -$21.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$21.6 million, -$17.6 million, and -$16.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.